VRDN FY 2017 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+20.0% YoY

Gross Profit

-$16M-390.2% margin

Operating Income

-$27M-662.8% margin

Net Income

-$27M-662.3% margin

EPS (Diluted)

$-20.66

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$52M

Total Liabilities

$14M

Stockholders' Equity

$39M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+20.0%
Gross Profit	-$16M	$789,000	-2079.7%
Operating Income	-$27M	-$13M	-112.1%
Net Income	-$27M	-$13M	-109.2%